logo

AARTIDRUGS vs DIVISLAB: Stock Comparison

AARTI DRUGS vs DIVI S LABORATORIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

DIVI S LABORATORIES is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E and a higher dividend yield, while DIVI S LABORATORIES shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 3; DIVISLAB leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSDIVISLAB

Valuation lens

What price are you paying?

Market CapContext only
₹3,478 Cr
₹2.42 L Cr
P/E RatioAARTIDRUGS has the lower reading
18.19x ✓
82.74x
P/B RatioAARTIDRUGS has the lower reading
2.25x ✓
14.44x
EPSDIVISLAB has the higher reading
₹20.93
₹110.21 ✓
Book ValueContext only
₹169.79
₹631.37
Dividend YieldAARTIDRUGS has the higher reading
0.5% ✓
0.33%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
DIVISLAB is the larger company
₹2.42 L Cr vs ₹3,478 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
18.19x vs 82.74x
P/B Ratio
AARTIDRUGS has a lower P/B
2.25x vs 14.44x
EPS
DIVISLAB has higher earnings per share
₹110.21 vs ₹20.93
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.5% vs 0.33%
Revenue Growth (TTM YoY)
DIVISLAB has faster revenue growth
9.5% vs 6.4%
EPS Growth (TTM YoY)
DIVISLAB has faster EPS growth
13.6% vs -12%
ROE
DIVISLAB has a higher ROE
15.6% vs 12.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSDIVISLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSDIVISLAB
Live Price₹380.05₹9,162
Day Change-2.2%-0.3%
Volume1.59 L10.41 L
52-Week High₹534₹9,740
52-Week Low₹318.95₹5,647.5
Distance from 52W High-28.83%-5.93%

Valuation

MetricAARTIDRUGSDIVISLAB
Market Cap₹3,478 Cr₹2.42 L Cr
P/E Ratio18.19x82.74x
P/B Ratio2.25x14.44x
EPS₹20.93₹110.21
Book Value₹169.79₹631.37
Dividend Yield0.5%0.33%

Growth

MetricAARTIDRUGSDIVISLAB
Revenue Growth (TTM YoY)6.4%9.5%
EPS Growth (TTM YoY)-12%13.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricAARTIDRUGSDIVISLAB
ROE12.05%15.6%
ROCE10.64%16.2%
Net Margin7.6%24.36%
Operating Margin9.19%33.3%
Debt to Equity0.3x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricAARTIDRUGSDIVISLAB
Promoter Holding54.07%▼ 0.36 pp51.88%
FII Holding2.26%▲ 0.74 pp20.38%▲ 0.18 pp
DII Holding10.24%▼ 0.05 pp19.17%▼ 0.21 pp
Public Holding33.43%▼ 0.32 pp8.58%▲ 0.04 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and DIVI S LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.